Trial Profile
A Phase I, Single-center, Open-label Fixed-sequence Study to Assess the Effects of PRN1008 on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Rilzabrutinib (Primary) ; Midazolam
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Principia Biopharma
- 27 Feb 2015 Status changed from recruiting to completed, according to Australian New Zealand Clinical Trials Registry record.
- 19 Dec 2014 New trial record